Mike Castagna - Happy to welcome Garrett to MannKind Family
Jun 9, 2018 18:25:23 GMT -5
edvarney, sportsrancho, and 6 more like this
Post by johnhindepost on Jun 9, 2018 18:25:23 GMT -5
Mike Castagna
@castagna2011
Following Following @castagna2011
More
… Happy to welcome Garrett to the MannKind family!
media.licdn.com/dms/image/C4E03AQFn7yKM7TWTsg/profile-displayphoto-shrink_200_200/0?e=1533772800&v=beta&t=n0uRqcRgXDOdei6Hgdrmea8rha8sKQLya6crrltj0oE
Garrett Ingram
Garrett Ingram
CMO, SVP
Greater New York City AreaPharmaceuticals
Current
MannKind Corporation, GLG (Gerson Lehrman Group)
Previous
Dexcom, Sanofi, Bristol-Myers Squibb
Education
East Carolina University
Summary
Senior Pharmaceutical, Biotech, and Device Executive. Over twenty years highly successful experience in marketing and market access delivering profitability through strategic planning, and execution of contracting, health economics, sales and marketing programs. Extensive marketing, launch, managed care, health economics & multi-product life-cycle management experience.
• Pharmaceutical launch expertise in US & Global managed markets across biologics, devices, small molecules in multiple therapeutic classes including diabetes, endocrine, oncology, cardiovascular, arthritis, pain, depression, MS, and rare disease specialty injectables, devices and consumer products.
• Consistently optimized profitability and patient outcomes in the managed care environment with Value Based partnerships.
• Developed and evolved systematic approach to pull through optimization with direct impact on share and profitability across business units and companies.
• Successfully managed multiple departments & teams ranging in a variety of settings. Full responsibility for operational & human resource management.
• Consistently exceeded organization, operational and marketing goals and sales performance expectations.
• Directed, marketed, and managed comprehensive healthcare organizations in both the public & private sectors.
Experience
MannKind Corporation
CMO
MannKind Corporation
June 2018 – Present (1 month)Westlake Village, California
GLG (Gerson Lehrman Group)
Council Member
GLG (Gerson Lehrman Group)
December 2017 – Present (7 months)
Dexcom
Senior Vice President, Managed Markets
Dexcom
June 2017 – December 2017 (7 months)San Diego, California
Sanofi
Vice President, US Country Head of Market Access at Sanofi NA, Sanofi Genzyme, & Sanofi Pasteur
Sanofi
January 2016 – December 2016 (1 year)
Sanofi
Vice President, Head of US Market Access NA Pharmaceuticals
Sanofi
February 2014 – December 2016 (2 years 11 months)Bridgewater, New Jersey
Bristol-Myers Squibb
Vice President, Market Access Strategy-Bristol Myers Squib
Bristol-Myers Squibb
April 2012 – January 2014 (1 year 10 months)Bristol Myers Squib
Novo Nordisk Pharmaceuticals
Senior Director, Managed Markets Strategy & Health Economic Outcomes
Novo Nordisk Pharmaceuticals
January 2006 – January 2012 (6 years 1 month)
Novo Nordisk A/S
Executive Director Health Economics & Outcomes Research
Novo Nordisk A/S
January 2006 – January 2012 (6 years 1 month)
Novo Nordisk
AVP, Managed Markets Strategy & Operations
Novo Nordisk
2006 – January 2012 (6 years)
@castagna2011
Following Following @castagna2011
More
… Happy to welcome Garrett to the MannKind family!
media.licdn.com/dms/image/C4E03AQFn7yKM7TWTsg/profile-displayphoto-shrink_200_200/0?e=1533772800&v=beta&t=n0uRqcRgXDOdei6Hgdrmea8rha8sKQLya6crrltj0oE
Garrett Ingram
Garrett Ingram
CMO, SVP
Greater New York City AreaPharmaceuticals
Current
MannKind Corporation, GLG (Gerson Lehrman Group)
Previous
Dexcom, Sanofi, Bristol-Myers Squibb
Education
East Carolina University
Summary
Senior Pharmaceutical, Biotech, and Device Executive. Over twenty years highly successful experience in marketing and market access delivering profitability through strategic planning, and execution of contracting, health economics, sales and marketing programs. Extensive marketing, launch, managed care, health economics & multi-product life-cycle management experience.
• Pharmaceutical launch expertise in US & Global managed markets across biologics, devices, small molecules in multiple therapeutic classes including diabetes, endocrine, oncology, cardiovascular, arthritis, pain, depression, MS, and rare disease specialty injectables, devices and consumer products.
• Consistently optimized profitability and patient outcomes in the managed care environment with Value Based partnerships.
• Developed and evolved systematic approach to pull through optimization with direct impact on share and profitability across business units and companies.
• Successfully managed multiple departments & teams ranging in a variety of settings. Full responsibility for operational & human resource management.
• Consistently exceeded organization, operational and marketing goals and sales performance expectations.
• Directed, marketed, and managed comprehensive healthcare organizations in both the public & private sectors.
Experience
MannKind Corporation
CMO
MannKind Corporation
June 2018 – Present (1 month)Westlake Village, California
GLG (Gerson Lehrman Group)
Council Member
GLG (Gerson Lehrman Group)
December 2017 – Present (7 months)
Dexcom
Senior Vice President, Managed Markets
Dexcom
June 2017 – December 2017 (7 months)San Diego, California
Sanofi
Vice President, US Country Head of Market Access at Sanofi NA, Sanofi Genzyme, & Sanofi Pasteur
Sanofi
January 2016 – December 2016 (1 year)
Sanofi
Vice President, Head of US Market Access NA Pharmaceuticals
Sanofi
February 2014 – December 2016 (2 years 11 months)Bridgewater, New Jersey
Bristol-Myers Squibb
Vice President, Market Access Strategy-Bristol Myers Squib
Bristol-Myers Squibb
April 2012 – January 2014 (1 year 10 months)Bristol Myers Squib
Novo Nordisk Pharmaceuticals
Senior Director, Managed Markets Strategy & Health Economic Outcomes
Novo Nordisk Pharmaceuticals
January 2006 – January 2012 (6 years 1 month)
Novo Nordisk A/S
Executive Director Health Economics & Outcomes Research
Novo Nordisk A/S
January 2006 – January 2012 (6 years 1 month)
Novo Nordisk
AVP, Managed Markets Strategy & Operations
Novo Nordisk
2006 – January 2012 (6 years)